APO Research
Talk to an analyst

APO RESEARCH · REPORT

Blood Plasma Derivatives

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Blood Plasma Derivatives Market Outlook and Growth Opportunities 2026

21 December 2025202 pages

Choose your research edition.

Industry ResearchBlood Plasma Derivatives Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Blood Plasma Derivatives Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Blood Plasma Derivatives Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Blood Plasma Derivatives Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Blood Plasma Derivatives Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Blood Plasma Derivatives market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Blood Plasma Derivatives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Blood Plasma Derivatives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Blood Plasma Derivatives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Blood Plasma Derivatives market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Blood Plasma Derivatives market include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Blood Plasma Derivatives market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Blood Plasma Derivatives and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Blood Plasma Derivatives revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Blood Plasma Derivatives market.

Blood Plasma Derivatives Segment by Company

Yuanda Shuyang

Takeda

Weiguang Bio

Tiantan Bio

CBPO

Shuanglin Bio

RAAS

Nanyue Bio

Hualan Bio

Boya Bio

Octapharma

LFB Group

KM Biologics

Kedrion

Grifols

CSL

BPL

Biotest

Blood Plasma Derivatives Segment by Type

Albumin

Coagulation Factor

Immune Globulin

Other

Blood Plasma Derivatives Segment by Application

Hospital

Retail Pharmacy

Other

Blood Plasma Derivatives Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Blood Plasma Derivatives status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Blood Plasma Derivatives key companies, revenue, market share, and recent developments.

3. To split the Blood Plasma Derivatives breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Blood Plasma Derivatives market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Blood Plasma Derivatives significant trends, drivers, influence factors in global and regions.

6. To analyze Blood Plasma Derivatives competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Plasma Derivatives market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Blood Plasma Derivatives and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Plasma Derivatives.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Blood Plasma Derivatives industry.

Chapter 3: Detailed analysis of Blood Plasma Derivatives company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Blood Plasma Derivatives in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Blood Plasma Derivatives in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Blood Plasma Derivatives Industry Trends Table 2. Blood Plasma Derivatives Industry Drivers Table 3. Blood Plasma Derivatives Industry Opportunities and Challenges Table 4. Blood Plasma Derivatives Industry Restraints Table 5. Global Blood Plasma Derivatives Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Blood Plasma Derivatives Revenue Share by Company (2021-2026) Table 7. Global Blood Plasma Derivatives Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Blood Plasma Derivatives Key Company Manufacturing Base & Headquarters Table 9. Global Blood Plasma Derivatives Company, Product Type & Application Table 10. Global Blood Plasma Derivatives Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Blood Plasma Derivatives by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Albumin Table 15. Significant Companies of Coagulation Factor Table 16. Significant Companies of Immune Globulin Table 17. Significant Companies of Other Table 18. Global Blood Plasma Derivatives Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Blood Plasma Derivatives Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Blood Plasma Derivatives Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Blood Plasma Derivatives Sales Value Share by Type (2021-2026) Table 22. Global Blood Plasma Derivatives Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Retail Pharmacy Table 25. Significant Companies of Other Table 26. Global Blood Plasma Derivatives Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Blood Plasma Derivatives Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Blood Plasma Derivatives Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Blood Plasma Derivatives Sales Value Share by Application (2021-2026) Table 30. Global Blood Plasma Derivatives Sales Value Share by Application (2027-2032) Table 31. Global Blood Plasma Derivatives Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Blood Plasma Derivatives Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Blood Plasma Derivatives Sales Value Share by Region (2021-2026) Table 34. Global Blood Plasma Derivatives Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Blood Plasma Derivatives Sales Value Share by Region (2027-2032) Table 36. Global Blood Plasma Derivatives Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Blood Plasma Derivatives Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Blood Plasma Derivatives Sales Value Market Share by Country (2021-2026) Table 39. Global Blood Plasma Derivatives Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Blood Plasma Derivatives Sales Value Market Share by Country (2027-2032) Table 41. Yuanda Shuyang Company Information Table 42. Yuanda Shuyang Business Overview Table 43. Yuanda Shuyang Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Yuanda Shuyang Blood Plasma Derivatives Product Portfolio Table 45. Yuanda Shuyang Recent Development Table 46. Takeda Company Information Table 47. Takeda Business Overview Table 48. Takeda Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Takeda Blood Plasma Derivatives Product Portfolio Table 50. Takeda Recent Development Table 51. Weiguang Bio Company Information Table 52. Weiguang Bio Business Overview Table 53. Weiguang Bio Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Weiguang Bio Blood Plasma Derivatives Product Portfolio Table 55. Weiguang Bio Recent Development Table 56. Tiantan Bio Company Information Table 57. Tiantan Bio Business Overview Table 58. Tiantan Bio Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Tiantan Bio Blood Plasma Derivatives Product Portfolio Table 60. Tiantan Bio Recent Development Table 61. CBPO Company Information Table 62. CBPO Business Overview Table 63. CBPO Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. CBPO Blood Plasma Derivatives Product Portfolio Table 65. CBPO Recent Development Table 66. Shuanglin Bio Company Information Table 67. Shuanglin Bio Business Overview Table 68. Shuanglin Bio Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Shuanglin Bio Blood Plasma Derivatives Product Portfolio Table 70. Shuanglin Bio Recent Development Table 71. RAAS Company Information Table 72. RAAS Business Overview Table 73. RAAS Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. RAAS Blood Plasma Derivatives Product Portfolio Table 75. RAAS Recent Development Table 76. Nanyue Bio Company Information Table 77. Nanyue Bio Business Overview Table 78. Nanyue Bio Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Nanyue Bio Blood Plasma Derivatives Product Portfolio Table 80. Nanyue Bio Recent Development Table 81. Hualan Bio Company Information Table 82. Hualan Bio Business Overview Table 83. Hualan Bio Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Hualan Bio Blood Plasma Derivatives Product Portfolio Table 85. Hualan Bio Recent Development Table 86. Boya Bio Company Information Table 87. Boya Bio Business Overview Table 88. Boya Bio Blood Plasma Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Boya Bio Blood Plasma Derivatives Product Portfolio Table 90. Boya Bio Recent Development Table 91. Octapharma Company Information Table 92. Octapharma Business Overview Table 93. Octapharma Blood Plasma Derivatives Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Octapharma Blood Plasma Derivatives Product Portfolio Table 95. Octapharma Recent Development Table 96. LFB Group Company Information Table 97. LFB Group Business Overview Table 98. LFB Group Blood Plasma Derivatives Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. LFB Group Blood Plasma Derivatives Product Portfolio Table 100. LFB Group Recent Development Table 101. KM Biologics Company Information Table 102. KM Biologics Business Overview Table 103. KM Biologics Blood Plasma Derivatives Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. KM Biologics Blood Plasma Derivatives Product Portfolio Table 105. KM Biologics Recent Development Table 106. Kedrion Company Information Table 107. Kedrion Business Overview Table 108. Kedrion Blood Plasma Derivatives Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Kedrion Blood Plasma Derivatives Product Portfolio Table 110. Kedrion Recent Development Table 111. Grifols Company Information Table 112. Grifols Business Overview Table 113. Grifols Blood Plasma Derivatives Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Grifols Blood Plasma Derivatives Product Portfolio Table 115. Grifols Recent Development Table 116. CSL Company Information Table 117. CSL Business Overview Table 118. CSL Blood Plasma Derivatives Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. CSL Blood Plasma Derivatives Product Portfolio Table 120. CSL Recent Development Table 121. BPL Company Information Table 122. BPL Business Overview Table 123. BPL Blood Plasma Derivatives Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. BPL Blood Plasma Derivatives Product Portfolio Table 125. BPL Recent Development Table 126. Biotest Company Information Table 127. Biotest Business Overview Table 128. Biotest Blood Plasma Derivatives Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Biotest Blood Plasma Derivatives Product Portfolio Table 130. Biotest Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Blood Plasma Derivatives Product Image Figure 2. Global Blood Plasma Derivatives Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Blood Plasma Derivatives Market Size (2021-2032) & (US$ Million) Figure 4. Global Blood Plasma Derivatives Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Albumin Image Figure 8. Coagulation Factor Image Figure 9. Immune Globulin Image Figure 10. Other Image Figure 11. Global Blood Plasma Derivatives Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Blood Plasma Derivatives Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Blood Plasma Derivatives Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Retail Pharmacy Image Figure 16. Other Image Figure 17. Global Blood Plasma Derivatives Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Blood Plasma Derivatives Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Blood Plasma Derivatives Sales Value Share by Application (2021-2032) Figure 20. Global Blood Plasma Derivatives Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Blood Plasma Derivatives Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Blood Plasma Derivatives Sales Value (2021-2032) & (US$ Million) Figure 23. North America Blood Plasma Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Blood Plasma Derivatives Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Blood Plasma Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Blood Plasma Derivatives Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Blood Plasma Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Blood Plasma Derivatives Sales Value (2021-2032) & (US$ Million) Figure 29. South America Blood Plasma Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Blood Plasma Derivatives Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Blood Plasma Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Blood Plasma Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Albumin
  • Coagulation Factor
  • Immune Globulin
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Yuanda Shuyang
  • Takeda
  • Weiguang Bio
  • Tiantan Bio
  • CBPO
  • Shuanglin Bio
  • RAAS
  • Nanyue Bio
  • Hualan Bio
  • Boya Bio
  • Octapharma
  • LFB Group
  • KM Biologics
  • Kedrion
  • Grifols
  • CSL
  • BPL
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Blood Plasma Derivatives Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Blood Plasma Derivatives Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Blood Plasma Derivatives Market Dynamics
  1. 2.1 Blood Plasma Derivatives Industry Trends
  2. 2.2 Blood Plasma Derivatives Industry Drivers
  3. 2.3 Blood Plasma Derivatives Industry Opportunities and Challenges
  4. 2.4 Blood Plasma Derivatives Industry Restraints
3 Blood Plasma Derivatives Market by Company
  1. 3.1 Global Blood Plasma Derivatives Company Revenue Ranking in 2025
  2. 3.2 Global Blood Plasma Derivatives Revenue by Company (2021-2026)
  3. 3.3 Global Blood Plasma Derivatives Company Ranking (2024-2026)
  4. 3.4 Global Blood Plasma Derivatives Company Manufacturing Base and Headquarters
  5. 3.5 Global Blood Plasma Derivatives Company Product Type and Application
  6. 3.6 Global Blood Plasma Derivatives Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Blood Plasma Derivatives Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Blood Plasma Derivatives Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Blood Plasma Derivatives Market by Type
  1. 4.1 Blood Plasma Derivatives Type Introduction
  2. 4.1.1 Albumin
  3. 4.1.2 Coagulation Factor
  4. 4.1.3 Immune Globulin
  5. 4.1.4 Other
  6. 4.2 Global Blood Plasma Derivatives Sales Value by Type
  7. 4.2.1 Global Blood Plasma Derivatives Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Blood Plasma Derivatives Sales Value by Type (2021-2032)
  9. 4.2.3 Global Blood Plasma Derivatives Sales Value Share by Type (2021-2032)
5 Blood Plasma Derivatives Market by Application
  1. 5.1 Blood Plasma Derivatives Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Blood Plasma Derivatives Sales Value by Application
  6. 5.2.1 Global Blood Plasma Derivatives Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Blood Plasma Derivatives Sales Value by Application (2021-2032)
  8. 5.2.3 Global Blood Plasma Derivatives Sales Value Share by Application (2021-2032)
6 Blood Plasma Derivatives Regional Value Analysis
  1. 6.1 Global Blood Plasma Derivatives Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Blood Plasma Derivatives Sales Value by Region (2021-2032)
  3. 6.2.1 Global Blood Plasma Derivatives Sales Value by Region: 2021-2026
  4. 6.2.2 Global Blood Plasma Derivatives Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Blood Plasma Derivatives Sales Value (2021-2032)
  7. 6.3.2 North America Blood Plasma Derivatives Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Blood Plasma Derivatives Sales Value (2021-2032)
  10. 6.4.2 Europe Blood Plasma Derivatives Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Blood Plasma Derivatives Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Blood Plasma Derivatives Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Blood Plasma Derivatives Sales Value (2021-2032)
  16. 6.6.2 South America Blood Plasma Derivatives Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Blood Plasma Derivatives Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Blood Plasma Derivatives Sales Value Share by Country, 2025 VS 2032
7 Blood Plasma Derivatives Country-level Value Analysis
  1. 7.1 Global Blood Plasma Derivatives Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Blood Plasma Derivatives Sales Value by Country (2021-2032)
  3. 7.2.1 Global Blood Plasma Derivatives Sales Value by Country (2021-2026)
  4. 7.2.2 Global Blood Plasma Derivatives Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Blood Plasma Derivatives Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Blood Plasma Derivatives Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Blood Plasma Derivatives Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yuanda Shuyang
  2. 8.1.1 Yuanda Shuyang Company Information
  3. 8.1.2 Yuanda Shuyang Business Overview
  4. 8.1.3 Yuanda Shuyang Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yuanda Shuyang Blood Plasma Derivatives Product Portfolio
  6. 8.1.5 Yuanda Shuyang Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Blood Plasma Derivatives Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Weiguang Bio
  14. 8.3.1 Weiguang Bio Company Information
  15. 8.3.2 Weiguang Bio Business Overview
  16. 8.3.3 Weiguang Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Weiguang Bio Blood Plasma Derivatives Product Portfolio
  18. 8.3.5 Weiguang Bio Recent Developments
  19. 8.4 Tiantan Bio
  20. 8.4.1 Tiantan Bio Company Information
  21. 8.4.2 Tiantan Bio Business Overview
  22. 8.4.3 Tiantan Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tiantan Bio Blood Plasma Derivatives Product Portfolio
  24. 8.4.5 Tiantan Bio Recent Developments
  25. 8.5 CBPO
  26. 8.5.1 CBPO Company Information
  27. 8.5.2 CBPO Business Overview
  28. 8.5.3 CBPO Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CBPO Blood Plasma Derivatives Product Portfolio
  30. 8.5.5 CBPO Recent Developments
  31. 8.6 Shuanglin Bio
  32. 8.6.1 Shuanglin Bio Company Information
  33. 8.6.2 Shuanglin Bio Business Overview
  34. 8.6.3 Shuanglin Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shuanglin Bio Blood Plasma Derivatives Product Portfolio
  36. 8.6.5 Shuanglin Bio Recent Developments
  37. 8.7 RAAS
  38. 8.7.1 RAAS Company Information
  39. 8.7.2 RAAS Business Overview
  40. 8.7.3 RAAS Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  41. 8.7.4 RAAS Blood Plasma Derivatives Product Portfolio
  42. 8.7.5 RAAS Recent Developments
  43. 8.8 Nanyue Bio
  44. 8.8.1 Nanyue Bio Company Information
  45. 8.8.2 Nanyue Bio Business Overview
  46. 8.8.3 Nanyue Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nanyue Bio Blood Plasma Derivatives Product Portfolio
  48. 8.8.5 Nanyue Bio Recent Developments
  49. 8.9 Hualan Bio
  50. 8.9.1 Hualan Bio Company Information
  51. 8.9.2 Hualan Bio Business Overview
  52. 8.9.3 Hualan Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hualan Bio Blood Plasma Derivatives Product Portfolio
  54. 8.9.5 Hualan Bio Recent Developments
  55. 8.10 Boya Bio
  56. 8.10.1 Boya Bio Company Information
  57. 8.10.2 Boya Bio Business Overview
  58. 8.10.3 Boya Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boya Bio Blood Plasma Derivatives Product Portfolio
  60. 8.10.5 Boya Bio Recent Developments
  61. 8.11 Octapharma
  62. 8.11.1 Octapharma Company Information
  63. 8.11.2 Octapharma Business Overview
  64. 8.11.3 Octapharma Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Octapharma Blood Plasma Derivatives Product Portfolio
  66. 8.11.5 Octapharma Recent Developments
  67. 8.12 LFB Group
  68. 8.12.1 LFB Group Company Information
  69. 8.12.2 LFB Group Business Overview
  70. 8.12.3 LFB Group Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  71. 8.12.4 LFB Group Blood Plasma Derivatives Product Portfolio
  72. 8.12.5 LFB Group Recent Developments
  73. 8.13 KM Biologics
  74. 8.13.1 KM Biologics Company Information
  75. 8.13.2 KM Biologics Business Overview
  76. 8.13.3 KM Biologics Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  77. 8.13.4 KM Biologics Blood Plasma Derivatives Product Portfolio
  78. 8.13.5 KM Biologics Recent Developments
  79. 8.14 Kedrion
  80. 8.14.1 Kedrion Company Information
  81. 8.14.2 Kedrion Business Overview
  82. 8.14.3 Kedrion Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Kedrion Blood Plasma Derivatives Product Portfolio
  84. 8.14.5 Kedrion Recent Developments
  85. 8.15 Grifols
  86. 8.15.1 Grifols Company Information
  87. 8.15.2 Grifols Business Overview
  88. 8.15.3 Grifols Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Grifols Blood Plasma Derivatives Product Portfolio
  90. 8.15.5 Grifols Recent Developments
  91. 8.16 CSL
  92. 8.16.1 CSL Company Information
  93. 8.16.2 CSL Business Overview
  94. 8.16.3 CSL Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  95. 8.16.4 CSL Blood Plasma Derivatives Product Portfolio
  96. 8.16.5 CSL Recent Developments
  97. 8.17 BPL
  98. 8.17.1 BPL Company Information
  99. 8.17.2 BPL Business Overview
  100. 8.17.3 BPL Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  101. 8.17.4 BPL Blood Plasma Derivatives Product Portfolio
  102. 8.17.5 BPL Recent Developments
  103. 8.18 Biotest
  104. 8.18.1 Biotest Company Information
  105. 8.18.2 Biotest Business Overview
  106. 8.18.3 Biotest Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Biotest Blood Plasma Derivatives Product Portfolio
  108. 8.18.5 Biotest Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst